All In Biotech

NDA 210251 · Gilead Sciences INC

Biktarvy

Bictegravir Sodium, Emtricitabine, Tenofovir Alafenamide Fumarate · Oral · Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: May 21, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Feb 7, 2018

Approved uses

9

Original approval plus efficacy supplements

Registered trials

120

36 Phase 3, 12 recruiting

FAERS reports

18,385

13,377 serious, 732 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and HBV who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of BIKTARVY. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients with HIV-1 and HBV who discontinue BIKTARVY. If appropriate, anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ] . WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning. Severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and HBV who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with...

What it is approved for

From the label in effect Sep 9, 2026.

BIKTARVY is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg: with no antiretroviral treatment history, or with an antiretroviral treatment history and not virologically suppressed, with no known or suspected substitutions associated with resistance to the integrase strand inhibitor class, emtricitabine, or tenofovir, or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir [see Dosage and Administration (2.4) , and Use in Specific Populations (8.1) ]. BIKTARVY is a three-drug combination of bictegravir (BIC), a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg: with no antiretroviral treatment history or with an antiretroviral treatment history and not virologically suppressed, with no known or suspected substitutions associated with resistance to the integrase strand inhibitor class, emtricitabine, or tenofovir, or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir. ( 1 )

Mechanism: BIKTARVY is a fixed dose combination of antiretroviral drugs bictegravir (BIC), emtricitabine (FTC), and tenofovir alafenamide (TAF) [see Microbiology (12.4) ] .

Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 30, 2025 Supplement 23 · Efficacy OrphanLabelLetter
  • Apr 24, 2024 Supplement 19 · Efficacy · priority review OrphanLetterLabel
  • Feb 23, 2024 Supplement 18 · Efficacy OrphanLabelLetter
  • Oct 14, 2022 Supplement 15 · Efficacy LetterLabel
  • Oct 7, 2021 Supplement 14 · Efficacy · priority review OrphanLetterLabel
  • Feb 24, 2021 Supplement 8 · Efficacy LetterLabel
  • Feb 5, 2021 Supplement 7 · Efficacy LabelLetter
  • Jun 18, 2019 Supplement 5 · Efficacy · priority review OrphanLetterLabel
  • Feb 7, 2018 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelOrphanLabelLetterReview
2 products under this application
  • BIKTARVY · BICTEGRAVIR SODIUM EQ 50MG BASE; EMTRICITABINE 200MG; TENOFOVIR ALAFENAMIDE FUMARATE EQ 25MG BASE · TABLET, ORAL · Prescription
  • BIKTARVY · BICTEGRAVIR SODIUM EQ 30MG BASE; EMTRICITABINE 120MG; TENOFOVIR ALAFENAMIDE FUMARATE EQ 15MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bictegravir" as an intervention, any sponsor and status, largest first.

All 120 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • bone density decreased6,649
  • chronic kidney disease3,668
  • bone loss3,491
  • tooth loss3,445
  • osteonecrosis3,405
  • multiple fractures3,153
  • renal failure3,059
  • osteoporosis2,794
  • pain2,549
  • renal injury2,489
  • emotional distress2,436
  • anxiety2,283

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
20151
20167
20171
2018363
20191,482
20205,609
20212,570
20222,257
20231,630
20241,854
20251,709
2026901

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Biktarvy (Bictegrav/Emtricit/Tenofov Ala)

2024 spending

$3.46B

Beneficiaries

92,246

840,772 claims

Per beneficiary

$37,466

$131.33 per unit

View as table
YearSpending
2020$1,775,846,507
2021$2,198,270,149
2022$2,703,581,195
2023$3,152,256,269
2024$3,456,061,331

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 130 on PubMed

Sponsor: Gilead Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.